Response to “letter concerning: Clewell (2019) incorporation of in vitro metabolism data and physiologically based pharmacokinetic modeling in a risk assessment for chloroprene.” (UIHT-2020-0053)

H. J. Clewell IIIa Research Triangle Park, Ramboll US Corporation, Charlotte, North Carolina, USACorrespondence[email protected]

J. L. Campbella Research Triangle Park, Ramboll US Corporation, Charlotte, North Carolina, USA

C. Van Landinghamb Ramboll US Corporation, Monroe, Louisiana, USA

A. Franzenb Ramboll US Corporation, Monroe, Louisiana, USA

M. Yoonc ToxStrategies, Inc., Cary, North Carolina, USA

D. E. Doddd Research Triangle Park, The Hamner Institutes for Health Sciences, North Carolina, USA

M. E. Andersend Research Triangle Park, The Hamner Institutes for Health Sciences, North Carolina, USA

P. R. Gentryc ToxStrategies, Inc., Cary, North Carolina, USA

show all

Click to increase image sizeClick to decrease image size

Acknowledgments

The approach for the quantitative estimation of the clearance of 1-CEO was suggested by Paul Schlosser, USEPA NCEA.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Response to “letter concerning: Clewell (2019) incorporation of in vitro metabolism data and physiologically based pharmacokinetic modeling in a risk assessment for chloroprene.” (UIHT-2020-0053)

Information for

Open access

Opportunities

Help and information

Response to “letter concerning: Clewell (2019) incorporation of in vitro metabolism data and physiologically based pharmacokinetic modeling in a risk assessment for chloroprene.” (UIHT-2020-0053)

Acknowledgments

Disclosure statement

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature